Suboptimal aminoglycoside dosing in critically ill patients

Therapeutic Drug Monitoring

Volumn 30, Issue 6, 2008, Pages 674-681

  Rea, Rhonda S ^a,d   Capitano, Blair ^a,e   Bies, Robert ^b   Bigos, Kristin L ^a,f   Smith, Randall ^a   Lee, Howard ^c  

^a UNIVERSITY OF PITTSBURGH   (United States)

^b UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^c University of California (Retired)   (United States)

^d Sanofi Aventis   (United States)

^e PFIZER INC   (United States)

^f NATIONAL INSTITUTE OF MENTAL HEALTH   (United States)

Author keywords

Aminoglycosides; Intensive care unit; Pharmacodynamics; Pharmacokinetics

Indexed keywords

GENTAMICIN; TOBRAMYCIN;

ADULT; AGED; ARTICLE; BODY WEIGHT; CONTROLLED STUDY; CRITICALLY ILL PATIENT; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG DOSE REGIMEN; FEMALE; GLOMERULUS FILTRATION RATE; GRAM NEGATIVE INFECTION; HUMAN; MAJOR CLINICAL STUDY; MALE; MAXIMUM PLASMA CONCENTRATION; MINIMUM INHIBITORY CONCENTRATION; PRIORITY JOURNAL; PSEUDOMONAS AERUGINOSA; PSEUDOMONAS INFECTION;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTI-BACTERIAL AGENTS; BACTERIA; BACTERIAL INFECTIONS; CRITICAL ILLNESS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG RESISTANCE, BACTERIAL; FEMALE; GENTAMICINS; HUMANS; INTENSIVE CARE UNITS; MALE; MICROBIAL SENSITIVITY TESTS; MIDDLE AGED; TOBRAMYCIN;

EID: 57749107966     PISSN: 01634356     EISSN: None     Source Type: Journal    
DOI: 10.1097/FTD.0b013e31818b6b2f     Document Type: Article

References (35)

1. Bryant RE, Hood AF, Hood CE, et al. Factors affecting mortality of Gram-negative rod bacteremia. Arch Intern Med. 1971;127:120-128.
2. Fried MA, Vosti KL. The importance of underlying disease in patients with Gram-negative bacteremia. Arch Intern Med. 1968;121:418-423.
3. Young LS, Meyer RD, Weinstein RJ, et al. Gram-negative rod bacteremia: microbiologic, immunologic, and therapeutic considerations. Ann Intern Med. 1977;86:456-471.
4. Georges B, Conil JM, Dubouix A, et al. Risk of emergence of Pseudomonas aeruginosa resistance to beta-lactam antibiotics in intensive care units. Crit Care Med. 2006;34:1636-1641.
5. National Nosocomial Infections Surveillance System. National Nosocomial Infections Surveillance (NNIS) System Report, data summary from January 1992 to June 2002. Am J Infect Control. 2002;30:458-475.
6. Flamm RK, Weaver MK, Thornsberry C, et al. Factors associated with relative rates of antibiotic resistance in Pseudomonas aeruginosa isolates tested in clinical laboratories in the United States from 1999 to 2002. Antimicrob Agents Chemother. 2004;48:2431-2436.
7. Spellberg B, Powers JH, Brass EP, et al. Trends in antimicrobial drug development: implications for the future. Clin Infect Dis. 2004;38:1279-1286.
8. Kollef M. Gram-negative bacterial resistance: evolving patterns and treatment paradigm. Clin Infect Dis. 2005;40:S85-S88.
9. Craig WA. Pharmacokinetic/pharmacodynamic parameters: rationale for antibacterial dosing of mice and men. Clin Infect Dis. 1998;26:1-12.
10. Moore RD, Lietman PS, Smith CR. Clinical response to aminoglycoside therapy: importance of the ratio of peak concentration to minimal inhibitory concentration. J Infect Dis. 1987;155:93-99.
11. Kashuba AD, Nafziger AN, Drusano GL, et al. Optimizing aminoglycoside therapy for nosocomial pnuemonia caused by gram-negative bacteria. Antimicrob Agents Chemother. 1999;43:623-629.
12. Burgess DS. Use of pharmacokinetics and pharmacodynamics to optimize antimicrobial treatment of Pseudomonas aeruginosa infections. Clin Infect Dis. 2005;40:S99-S104.
13. Nicolau DP, Freeman CD, Belliveau PP, et al. Experience with a once-daily aminoglycoside program administered to 2,184 adult patients. Antimicrob Agent Chemother. 1995;39:650-655.
14. Rea RS, Bigos K, Bies R, et al. Suboptimal aminoglycoside dosing in critically ill patients. Crit Care Med. 2005;33(Suppl):A171.
15. Rivers E, Nguyen B, Haystad S, et al. Early goal-directed therapy in the treatment of severe sepsis and septic shock. N Engl J Med. 2001;345:1368-1377.
16. Dasta JF, Armstrong DK. Variability in aminoglycoside pharmacokinetics in critically ill surgical patients. Crit Care Med. 1988;16:327-330.
17. Wolfe T, Dasta J. Comment: once-daily aminoglycoside dosing in critically ill patients. Ann Pharmacother. 1998;32:1109-1110.
18. Tang GJ, Tang JJ, Lin BS, et al. Factors affecting gentamicin pharmacokinetics in septic patients. Acta Anaesthesiol Scand. 1999;43:726-730.
19. Barletta JF, Johnson SB, Nix DE, et al. Population pharmacokinetics of aminoglycosides in critically ill trauma patients on once-daily regimens. J Trauma. 2000;49:869-872.
20. Buijk SE, Mouton JW, Gyssens IC, et al. Experience with a once-daily dosing program of aminoglycosides in critically ill patients. Intensive Care Med. 2002;28:936-942.
21. Manjunath G, Sarnak MJ, Levey AS. Estimating the glomerular filtration rate: Dos and don'ts for assessing kidney function. Postgrad Med Online [serial online] 2001;110:1-2. (Available from Healthcare Information Group, Berwyn, PA. Assessed August 2, 2008).
22. NONMEM [computer program]. Version 5.1. San Francisco, CA: University of California; 1992.
23. Sheiner LB, Rosenberg B, Marathe VV. Estimation of population characteristics of pharmacokinetic parameters from routine clinical data. J Pharmacokinet Biopharm. 1977;5:445-479.
24. Noone P, Pattison JR, Davies DG. The effective use of gentamicin in life-threatening sepsis. Postgrad Med J. 1974;50(Suppl 7):9-16.
25. Moore RD, Smith CR, Lietman PS. Association of aminoglycoside plasma levels with therapeutic outcome in gram-negative pneumonia. Am J Med. 1984;77:657-662.
26. Kashuba AD, Bertino JS Jr, Nafziger AN. Dosing of aminoglycosides to rapidly attain pharmacodynamic goals and hasten therapeutic response by using individualized pharmacokinetic monitoring of patients with pneumonia caused by gram-negative organisms. Antimicrob Agent Chemother. 1998;42:1842-1844.
27. Drusano GL, Ambrose PG, Bhavnani SM, et al. Back to the future: using aminoglycosides again and how to dose them optimally. Clin Infect Dis. 2007;45:753-760.
28. Finnell DL, Davis GA, Cropp CD, et al. Validation of the Hartford nomogram in trauma surgery patients. Ann Pharmacother. 1998;32:417-421.
29. Xuan D, Nicolau DP, Nightingale CH. Population pharmacokinetics of gentamicin in hospitalized patients receiving once-daily dosing. Int J Antimicrob Agents. 2004;23:291-295.
30. Dager WE. Aminoglycoside pharmacokinetics: volume of distribution in specific adult patient subgroups. Ann Pharmacother. 1994;28:944-951.
31. Tholl DA, Shikuma LR, Miller TQ, et al. Physiologic response of stress and aminoglycoside clearance in critically ill patients. Crit Care Med. 1993;21:248-251.
32. Hatala R, Dinh T, Cook DJ. Once-daily aminoglycoside dosing in immunocompetent adults: a meta-analysis [see comment]. Ann Intern Med. 1996;124:717-725.
33. Ali MZ, Goetz MB. A meta-analysis of the relative efficacy and toxicity of single daily dosing versus multiple daily dosing of aminoglycosides [see comment]. Clin Infect Dis. 1997;24:796-809.
34. Hyatt JM, McKinnon PS, Zimmer GS, et al. The importance of pharmacokinetic/pharmacodynamic surrogate markers to outcome: focus on antibacterial agents. Clin Pharmacokinet. 1995;28:143-160.
35. Macdonald I, Staatz CE, Jelliffe RW, et al. Evaluation and comparison of simple multiple model, richer data multiple model, and sequential interacting multiple model (IMM) Bayesian analyses of gentamicin and vancomycin data collected from patients undergoing cardiothoracic surgery. Ther Drug Monit. 2008;30:67-74.